ReviewDiabetes technology & therapeutics2020
Recent Advances in Insulin Therapy.
Review in Diabetes technology & therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.Journal of diabetes research · 2024Pooled it
- Intersecting Molecular Pathways in Cardiovascular Disease and Diabetes Mellitus: Emerging Roles of Inflammation and Therapeutics.Diabetes/metabolism research and reviews · 2026Review
- Risk Factors of Diabetic Bladder Dysfunction in Patients with Type 2 Diabetes Mellitus: A Case-Control Study in Shenzhen, China.International urogynecology journal · 2026Article
- Impact of concomitant use of antiplatelet agents on the production of anti-insulin antibodies in patients with type 2 diabetes treated with insulin analogues.Diabetology international · 2025Article
- Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)-Special Interest Group in Diabetes.European geriatric medicine · 2025Review
- The health economics of insulin therapy: How do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes.Diabetes, obesity & metabolism · 2025Article
- Article
- Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.Current pharmaceutical biotechnology · 2025Review
- The blood glucose control levels and influencing factors analysis among diabetes patients in rural areas of Guangxi, China.Frontiers in endocrinology · 2025Article
- Identification and Characterization of a Novel Insulin-like Receptor (Biomolecules · 2024Article
- Improving glycemic control by transitioning from the MiniMedEndocrine journal · 2024Observational
- New guideline of the European Medicines Agency (EMA) on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus.Diabetologia · 2024Article
- Prandial Insulins: A Person-Centered Choice.Current diabetes reports · 2024Review
- Insulin Use During Gestational and Pre-existing Diabetes in Pregnancy: A Systematic Review of Study Design.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Diabetic Cardiomyopathy-From Basics through Diagnosis to Treatment.Biomedicines · 2024Review
- 100 Years since the Discovery of Insulin, from Its Discovery to the Insulins of the Future.Biomedicines · 2024Review
- The Current and Promising Oral Delivery Methods for Protein- and Peptide-Based Drugs.International journal of molecular sciences · 2024Review
- Effect of Gegen Qinlian Decoction on the regulation of gut microbiota and metabolites in type II diabetic rats.Frontiers in microbiology · 2024Article
- Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin therapy has advanced remarkably over the past few decades. Ultra-rapid-acting and ultra-long-acting insulin analogs are now commercially available. Many additional insulin formulations are in development. This review outlines recent advances in insulin therapy and novel therapies in development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.